- Home
- MVIS vs ALDX Comparison
MVIS vs ALDX Comparison
Compare MVIS & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVIS
- ALDX
- Stock Information
- Founded
- MVIS 1993
- ALDX 2004
- Country
- MVIS United States
- ALDX United States
- Employees
- MVIS N/A
- ALDX N/A
- Industry
- MVIS Industrial Machinery/Components
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- MVIS Technology
- ALDX Health Care
- Exchange
- MVIS Nasdaq
- ALDX Nasdaq
- Market Cap
- MVIS 308.8M
- ALDX 304.9M
- IPO Year
- MVIS 1996
- ALDX 2014
- Fundamental
- Price
- MVIS $1.50
- ALDX $6.69
- Analyst Decision
- MVIS Buy
- ALDX Strong Buy
- Analyst Count
- MVIS 4
- ALDX 2
- Target Price
- MVIS $2.67
- ALDX $10.00
- AVG Volume (30 Days)
- MVIS 8.6M
- ALDX 352.5K
- Earning Date
- MVIS 03-03-2025
- ALDX 03-06-2025
- Dividend Yield
- MVIS N/A
- ALDX N/A
- EPS Growth
- MVIS N/A
- ALDX N/A
- EPS
- MVIS N/A
- ALDX N/A
- Revenue
- MVIS $8,147,000.00
- ALDX N/A
- Revenue This Year
- MVIS N/A
- ALDX N/A
- Revenue Next Year
- MVIS $700.00
- ALDX N/A
- P/E Ratio
- MVIS N/A
- ALDX N/A
- Revenue Growth
- MVIS 277.53
- ALDX N/A
- 52 Week Low
- MVIS $0.80
- ALDX $2.71
- 52 Week High
- MVIS $2.70
- ALDX $6.92
- Technical
- Relative Strength Index (RSI)
- MVIS 51.55
- ALDX 74.28
- Support Level
- MVIS $1.28
- ALDX $6.49
- Resistance Level
- MVIS $1.93
- ALDX $6.92
- Average True Range (ATR)
- MVIS 0.19
- ALDX 0.31
- MACD
- MVIS -0.00
- ALDX 0.09
- Stochastic Oscillator
- MVIS 33.85
- ALDX 87.84
About MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.